Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.
Reduces elevated intraocular pressure (IOP). Sold as Travatan, Travatan Z, Izba, Idose Tr. Every FDA application for this active ingredient: 4 branded and 10 generic.
As of Nov 15, 2026, FDA lists 14 applications for Travoprost (sold as Travatan, Travatan Z, Izba and others), first approved Mar 16, 2001, with 4 new uses approved and 0 published complete response letters.
First approved: Mar 16, 2001
Applications: 14
New uses approved: 4
Complete response letters: 0
Medicare spending, 2025: $181M
First approved in the EU: Nov 27, 2001
Medicare Spending
CMS Part D and Part B, 2025, before manufacturer rebates; matched by generic name
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient.Drugs@FDA
Sandoz
Novartis
Apotex
Mylan
Alembic
Lupin
Par Pharm